Safety of CD34
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
14 Jun 2019
14 Jun 2019
Historique:
received:
18
09
2018
accepted:
20
02
2019
entrez:
27
3
2019
pubmed:
27
3
2019
medline:
27
3
2019
Statut:
epublish
Résumé
Although the risk of developing lymphoma has decreased in the highly active antiretroviral therapy era, this cancer remains the major cause of mortality in HIV-infected patients. Autologous hematopoietic stem cell transplantation (ASCT) outcome does not differ for HIV-infected versus HIV-uninfected patients. We propose to develop a new treatment for HIV-associated high-risk lymphoma based on autologous transplantation of two genetically modified products: CD4
Identifiants
pubmed: 30911587
doi: 10.1016/j.omtm.2019.02.006
pii: S2329-0501(19)30023-3
pmc: PMC6416524
doi:
Types de publication
Journal Article
Langues
eng
Pagination
303-309Références
J Virol. 2004 Jan;78(2):568-75
pubmed: 14694088
Mol Ther. 2007 May;15(5):1024-33
pubmed: 17356541
Gene Ther. 2008 Sep;15(17):1210-22
pubmed: 18449216
Nat Biotechnol. 2008 Jul;26(7):808-16
pubmed: 18587387
J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):590-8
pubmed: 18645512
N Engl J Med. 2009 Feb 12;360(7):692-8
pubmed: 19213682
Br J Cancer. 2009 Mar 10;100(5):840-7
pubmed: 19223894
Clin Infect Dis. 2010 Jun 15;50(12):1672-9
pubmed: 20450419
Sci Transl Med. 2010 Jun 16;2(36):36ra43
pubmed: 20555022
Cell Transplant. 2011;20(3):351-70
pubmed: 20875226
Blood. 2011 Mar 10;117(10):2791-9
pubmed: 21148083
N Engl J Med. 2014 Mar 6;370(10):901-10
pubmed: 24597865
Mol Ther Nucleic Acids. 2015 Apr 14;4:e236
pubmed: 25872029
Mol Ther Methods Clin Dev. 2014 Feb 12;1:11
pubmed: 26015947
Curr Opin Virol. 2015 Oct;14:24-9
pubmed: 26143158
Blood. 2016 Aug 25;128(8):1050-8
pubmed: 27297790
Bone Marrow Transplant. 2016 Dec;51(12):1609-1611
pubmed: 27595283
J Gene Med. 2018 Feb;20(2-3):e3006
pubmed: 29552747